American International Group, Inc. Rain Therapeutics Inc. Transaction History

American International Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.84 - $1.22 $254 - $369	303 Added 3.57%	8,784 $10,000
Q3 2023 Nov 13, 2023	BUY	$0.82 - $1.42 $246 - $427	301 Added 3.68%	8,481 $7,000
Q2 2023 Aug 04, 2023	BUY	$1.09 - $9.93 $8,916 - $81,227	8,180 New	8,180 $9,000
Q2 2022 Aug 12, 2022	SELL	$2.21 - $5.56 $17,456 - $43,918	-7,899 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.07 - $13.68 $2,818 - $7,606	-556 Reduced 6.58%	7,899 $40,000
Q4 2021 Feb 11, 2022	BUY	$11.91 - $17.0 $51,403 - $73,372	4,316 Added 104.28%	8,455 $109,000
Q3 2021 Nov 12, 2021	SELL	$13.21 - $20.91 $250 - $397	-19 Reduced 0.46%	4,139 $62,000
Q2 2021 Aug 13, 2021	BUY	$15.08 - $20.3 $62,702 - $84,407	4,158 New	4,158 $65,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.